



# Breast cancer in men

**AUTHORS:** William J Gradishar, MD, Kathryn J Ruddy, MD, MPH

**SECTION EDITORS:** Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C), Claudine Isaacs, MD

**DEPUTY EDITOR:** Sadhna R Vora, MD

---

All topics are updated as new evidence becomes available and our [peer review process](#) is complete.

Literature review current through: **Oct 2023**.

This topic last updated: **Nov 03, 2023**.

---

## INTRODUCTION

Breast cancer in men is rare [1,2]. Although it shares many similarities with cancer of the breast in women, there are also important differences [3,4]. This topic will review issues specific to men with breast cancer. An overview of breast cancer in women and topics related to the treatment of breast cancer are discussed in detail separately.

- (See "[Clinical features, diagnosis, and staging of newly diagnosed breast cancer](#)".)
- (See "[Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer](#)".)
- (See "[General principles of neoadjuvant management of breast cancer](#)".)
- (See "[Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer](#)".)
- (See "[Adjuvant systemic therapy for HER2-positive breast cancer](#)".)
- (See "[Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer](#)".)
- (See "[Overview of the approach to metastatic breast cancer](#)".)

## EPIDEMIOLOGY AND RISK FACTORS

In the United States and United Kingdom, male breast cancer represents between 0.5 and 1 percent of all breast cancers diagnosed each year [1,5]. In the United States, breast cancer in men accounts for less than 0.5 percent of all cancer diagnoses in men [5]. By contrast, in Tanzania and areas of central Africa, male breast cancer accounts for up to 6 percent of all breast cancers [6]. Higher rates of male breast cancer in central and eastern Africa may be related to endemic hepatic infectious diseases that lead to hyperestrogenism [7,8].

As with women, the incidence of breast cancer in men rises with age, and men tend to be approximately 5 to 10 years older than women at the time of diagnosis [4,9-14]. The annual incidence of breast cancer in men appears to be rising; one report suggests that incidence has increased 26 percent over the past 25 years [15].

Breast cancers in men appear to share some of the risk factors associated with postmenopausal breast cancer in women [4]. Systematic reviews of the literature have summarized the factors associated with breast cancer in men, and these are reviewed below [16,17]. Despite these reported associations, the vast majority of men with breast cancer have no identifiable risk factors.

**Genetics and family history** — Men with breast cancer should be referred for genetic counseling and testing, as discussed elsewhere. (See "[Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes](#)", section on 'Concerning personal or family history'.)

As with breast cancer in women, a family history of breast cancer in a first-degree relative is associated with an increased risk of breast cancer among men. Approximately 15 to 20 percent of men with breast cancer have a family history of the disease compared with only 7 percent of the general male population [11]. As is the case in women, two breast/ovarian cancer genes, *BRCA1* and *BRCA2*, which are inherited in an autosomal-dominant pattern, give rise to the majority of known cases of hereditary breast cancer. (See "[Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes](#)" and "[Overview of hereditary breast and ovarian cancer syndromes](#)".)

The risk for male breast cancer appears to be higher with inherited *BRCA2* rather than *BRCA1* mutations [18-23]. Men who inherit germline *BRCA2* mutations have an estimated 6 percent lifetime absolute risk of breast cancer; this represents a 100-fold higher risk than in the general male population [23,24]. (See "[Risk factors for prostate cancer](#)", section on 'Family history and

genetic factors' and ["Cancer risks and management of BRCA1/2 carriers without cancer"](#), section on 'Male breast cancer'.)

The incidence of *BRCA* mutations varies based upon ethnicity and strength of family history ( [table 1](#)) [20,25-35]. Of men with breast cancer, up to 14 percent have a deleterious *BRCA2* mutation; *BRCA1* mutations occur very rarely, except in individuals of Ashkenazi Jewish ethnicity. One study found that 4.5 percent of Ashkenazi Jewish men presenting with breast cancer have a *BRCA1* mutation [25,35]. Because of this, all men diagnosed with breast cancer should be referred for genetic counseling and *BRCA* testing. Cancer surveillance of men with a *BRCA* mutation is discussed separately. (See ["Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes"](#) and ["Cancer risks and management of BRCA1/2 carriers without cancer"](#).)

Genes other than *BRCA* may be involved in predisposition to breast cancer in men: mutations in the phosphatase and tensin homolog (*PTEN*) tumor suppressor gene (Cowden syndrome), tumor protein p53 (*TP53*; Li-Fraumeni syndrome), partner and localizer of *BRCA2* (*PALB2*), and mismatch repair genes (Lynch syndrome) have all been associated with an increased risk of breast cancer in men [36-38]. However, while such findings may raise the relative risk of breast cancer in men in whom the mutation was identified (compared with men without such mutation), the absolute risk of male breast cancer is still quite low. Therefore, we would not advise screening mammography or prophylactic mastectomy in affected male individuals. (See ["PTEN hamartoma tumor syndromes, including Cowden syndrome"](#) and ["Li-Fraumeni syndrome"](#) and ["Overview of hereditary breast and ovarian cancer syndromes"](#), section on 'PALB2' and ["Overview of hereditary breast and ovarian cancer syndromes"](#), section on 'MSH1, MLH1, MSH6, PMS2, and EPCAM (Lynch syndrome)').

**Alterations of the estrogen to androgen ratio** — Excessive estrogen stimulation may be due to hormonal therapies (eg, estrogen-containing compounds or testosterone), hepatic dysfunction, obesity, marijuana use, thyroid disease, or an inherited condition, such as Klinefelter syndrome.

Klinefelter syndrome is a rare condition resulting from the inheritance of an additional X chromosome [9,39-41]. Klinefelter syndrome consists of atrophic testes, gynecomastia, high serum concentrations of gonadotropins (follicle-stimulating hormone, luteinizing hormone), and low serum testosterone levels; the net effect is a high ratio of estrogen to testosterone. (See ["Causes of primary hypogonadism in males"](#).)

Few carefully conducted epidemiologic studies have been undertaken focusing on this association due to the rarity of both Klinefelter syndrome and male breast cancer. The largest

cohort study of 3518 men who were cytogenetically diagnosed with Klinefelter syndrome found 19- and 58-fold increases in incidence of and mortality from breast cancer, respectively, compared with the general population [42]. Additional studies are needed to clarify which men with Klinefelter syndrome are at a high risk of developing breast cancer and to define the contribution of possible predisposing factors, including altered endogenous hormones.

The role of breast cancer screening in men with Klinefelter syndrome is unclear. Although routine mammography is not advocated for all affected men, the importance of patient education, self-examination, and regular clinician examinations is stressed [42]. (See "[Sex chromosome abnormalities](#)", section on '[47,XXY Klinefelter syndrome](#)'.)

**Primary testicular conditions** — Testicular conditions associated with an increased risk of breast cancer in men include orchitis, undescended testes (cryptorchidism), and testicular injury [9,13,43]. While speculative, it may be that these conditions may be associated with lower androgen production, resulting in a higher than normal estrogen to androgen ratio.

**Prior cancer treatments** — Prior chest radiation is a risk factor for breast cancer in females, and one study suggests that it is also a risk factor in males [44]. In a cohort study in 3077 male survivors with Hodgkin lymphoma (HL) treated at age  $\leq 51$  years, after a 20-year median follow-up, male HL survivors had a 23-fold increase in breast cancer compared with males in the general population, with a 40-year cumulative breast cancer incidence of 0.7 percent. Treatment with chest radiotherapy was associated with increased incidence of male breast cancer irrespective of whether alkylating chemotherapy was administered.

---

## PRESENTATION

**Clinical characteristics** — Male breast cancer has typically been diagnosed at a more advanced stage than female breast cancer, most likely due to a lack of awareness that men can develop breast cancer and absence of routine screening exams [45]. Nevertheless, one analysis suggests that the majority of men are diagnosed with early-stage disease (95 percent) and only 3.8 percent present with de novo metastatic disease [46,47].

Most men with breast cancer generally present with a painless, firm mass that is usually subareolar, with nipple involvement in 40 to 50 percent of cases [11,48]. The left breast is involved slightly more often than the right, and less than 1 percent of cases are bilateral. There may be associated skin changes, including nipple retraction, ulceration, or fixation of the mass to the skin or underlying tissues. Axillary adenopathy is typically palpable in advanced cases.

**Pathologic characteristics** — Although most histologic subtypes of breast cancer seen in women are also present in men, men with breast cancer are rarely diagnosed with lobular carcinomas [49].

Approximately 85 to 90 percent of breast cancers in men are invasive ductal carcinomas [15,46]. By contrast, lobular cancers accounted for 1.5 percent of cases in one series of 2000 men [15] and only 0.5 percent in another series [47], while they account for up to 15 percent of cases in women [50]. The lack of a lobular histologic subtype is due to lack of acini and lobules in the normal male breast, although these can be induced in the context of estrogenic stimulation. (See "[Pathology of breast cancer](#)".)

In addition to differences in the invasive carcinoma, there are differences in the incidence and clinical characteristics of ductal carcinoma in situ (DCIS) (see "[Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis](#)" and "[Paget disease of the breast \(PDB\)](#)" and "[Inflammatory breast cancer: Clinical features and treatment](#)"):

- DCIS accounts for a significantly higher proportion of breast cancers in women compared with men (approximately 20 versus 7 to 11 percent, respectively) [15,51,52].
- DCIS in men tends to occur at a later age, presents more frequently in an intraductal papillary form, and is more often low grade [52,53].

Paget disease and inflammatory breast cancer have rarely been described in men [54-57].

**Breast cancer subtype** — As in postmenopausal women, the most common subtype of breast cancer in men is hormone receptor positive [11,14,15,58].

A worldwide consortium effort retrospectively evaluated the characteristics of almost 1500 male breast cancer patients for which tissue was available and found that 99 percent were estrogen receptor positive, 81 percent were progesterone receptor positive, and 97 percent were androgen receptor positive [46]. Immunohistochemistry evaluations from this study found that 42 percent were luminal A-like, 42 percent were luminal B-like, 8.7 percent were human epidermal growth factor receptor 2 (HER2) positive, and 0.3 percent were triple-negative.

There are differences in the molecular characteristics of breast cancer associated with both age and ethnicity, although these do not appear to influence survival outcomes. This was shown in a registry study involving 829 men with primary breast cancer (71, 11, and 7 percent who were non-Hispanic White, Hispanic, or non-Hispanic Black, respectively) [58]. Major findings were:

- Hormone receptor-positive/HER2-negative, HER2-positive, and triple-negative breast cancers were identified in 82, 15, and 4 percent of cases, respectively.

- Younger patients were more likely to be diagnosed with a HER2-positive tumor.
- Non-Hispanic Black men were more likely to have triple-negative breast cancer compared with non-Hispanic White or Hispanic men (9 versus 3 and 6 percent, respectively).

---

## DIAGNOSTIC EVALUATION AND STAGING

The approach to the male patient who presents with a suspicious breast mass is similar to that of women and includes mammography and biopsy. (See "[Clinical manifestations, differential diagnosis, and clinical evaluation of a palpable breast mass](#)" and "[Diagnostic evaluation of suspected breast cancer](#)" and "[Clinical features, diagnosis, and staging of newly diagnosed breast cancer](#)".)

**Mammography** — The mammogram is abnormal in 80 to 90 percent of men with breast cancer and can usually distinguish between malignancy and gynecomastia [59-61]. In one study, the reported sensitivity and specificity rates of mammography were 92 and 90 percent, respectively [59]. Radiographic features suggestive of malignancy include eccentricity to the nipple, spiculated margins, and microcalcifications. By contrast, gynecomastia typically appears as a round or triangular area of increased density positioned symmetrically in the retroareolar region. In rare cases, concurrent gynecomastia can mask a malignant lesion [60,61]. (See "[Breast imaging for cancer screening: Mammography and ultrasonography](#)".)

**Biopsy** — Any suspicious mass requires biopsy to confirm the diagnosis and to assay for estrogen receptor and progesterone receptor content as well as human epidermal growth factor receptor 2 status. Although fine needle aspiration (FNA) cytology can provide adequate diagnostic material in many cases, avoiding open or surgical biopsy [62-64], up to one-fourth of samples are insufficient for diagnosis [62]. Compared with FNA, core needle biopsy offers a more definitive histologic diagnosis, avoids inadequate samples, and usually distinguishes between invasive versus in situ cancer. If inadequate tissue is obtained, an open biopsy should be performed. (See "[Breast biopsy](#)".)

---

## DIFFERENTIAL DIAGNOSIS

The differential diagnosis of a breast mass in a man includes [65]:

- **Gynecomastia** – Gynecomastia typically presents as bilateral, symmetric breast enlargement with poorly defined borders. Unlike breast cancer, there is usually no evidence of fixation to the underlying chest wall, and it is not associated with skin changes

or axillary lymphadenopathy. (See ["Epidemiology, pathophysiology, and causes of gynecomastia"](#).)

- **Pseudogynecomastia** – In contrast to gynecomastia, pseudogynecomastia represents an increase in breast fat rather than glandular tissue, which can generally be appreciated on clinical exam. (See ["Clinical features, diagnosis, and evaluation of gynecomastia in adults"](#), section on 'Pseudogynecomastia'.)
- **Infections** – This includes breast abscess or other skin infections involving the chest wall. Typically, it presents as a localized and painful inflammation, often associated with systemic symptoms (eg, fever and malaise). (See ["Primary breast abscess"](#).)
- **Lipoma** – These are ovoid-shaped breast masses comprised of fat. Lipomas are the most common benign soft-tissue neoplasm and rarely cause symptoms. (See ["Overview of benign lesions of the skin"](#), section on 'Lipoma'.)
- **Pseudoangiomatous stromal hyperplasia** – Pseudoangiomatous stromal hyperplasia (PASH) is characterized as a benign, stromal proliferation. It presents as either a mass or thickening and on imaging is characterized as a solid, well-defined, noncalcified mass. (See ["Overview of benign breast diseases"](#), section on 'Pseudoangiomatous stromal hyperplasia'.)
- **Granular cell tumor** – Granular cell tumors are usually benign, submucosal tumors that arise from Schwann cells. They most commonly occur in the oropharynx, skin, subcutaneous tissue, or breasts. The clinical presentation and imaging evaluation of these tumors can mirror invasive breast cancer. Therefore, diagnosis often requires tissue analysis, which is obtained at core needle biopsy. (See ["Benign lesions of the esophagus"](#), section on 'Granular cell tumors'.)
- **Fibromatosis** – Fibromatoses (or desmoid tumors) are locally aggressive tumors with no known potential for metastasis or dedifferentiation. The diagnosis requires histologic examination of a biopsy specimen. (See ["Desmoid tumors: Epidemiology, molecular pathogenesis, clinical presentation, diagnosis, and local therapy"](#).)
- **Metastatic disease** – Although rare, metastases from another primary cancer can present as a breast mass. A biopsy is necessary to rule out a primary versus metastatic lesion.

Other rare tumors that occur in men include schwannoma, myofibroblastoma, and hemangiomas. In addition, other benign breast lesions that are more commonly seen in

women should be considered. These are discussed in more detail separately. (See "[Overview of benign breast diseases](#)".)

---

## STAGING WORKUP

The diagnostic evaluation and staging system used for breast cancers in men are the same as for women with breast cancer. (See "[Clinical features, diagnosis, and staging of newly diagnosed breast cancer](#)".)

Breast cancer is classified according to the eighth edition Tumor, Node, Metastasis (TNM) staging system developed by the American Joint Committee on Cancer (AJCC) and endorsed by the Union for International Cancer Control (UICC) [66]. (See "[Tumor, node, metastasis \(TNM\) staging classification for breast cancer](#)".)

As in women, stage, tumor size, and axillary lymph node status are the most important factors influencing outcome in breast cancers in men. (See '[Prognosis](#)' below.)

---

## NON-METASTATIC DISEASE

**Differences compared with the approach in women** — In general, the approach to early breast cancer in men mirrors that for women. However, there are noteworthy exceptions. In particular:

- Men with early-stage breast cancer typically proceed with simple mastectomy rather than breast-conserving therapy because of their small volume of breast tissue. However, decision-making between the two options should proceed in an analogous fashion as for women. Specifically, men who have sufficient breast tissue to permit breast conservation may proceed with this strategy, barring any contraindications, followed by adjuvant radiation. (See '[Surgical treatment](#)' below and "[Breast-conserving therapy](#)", section on '[Absolute contraindications for BCT](#)' and "[Breast-conserving therapy](#)", section on '[Relative contraindications for BCT](#)'.)
- For those with hormone receptor-positive disease, we suggest adjuvant [tamoxifen](#) rather than an aromatase inhibitor (AI), given insufficient evidence to support AI monotherapy for men [67], and fewer side effects compared with AI with gonadotropin-releasing hormone agonists (GnRHa). For those with contraindications to tamoxifen (eg, hypercoagulable state), an AI with GnRHa may be administered. (See '[Endocrine therapy](#)' below.)

**Surgical treatment** — The surgical approach to treatment of breast cancer in men is similar to that of women and depends on the extent of disease at presentation. This is discussed below.

**Early-stage disease** — Although there have been no randomized trials, most men with early-stage disease (T1 to T2, N0 to N1) undergo a simple mastectomy rather than a mastectomy with pectoral muscle removal. For men who want to avoid mastectomy, limited data suggest that breast-conserving surgery is a reasonable alternative, provided there is enough breast tissue to ensure that adequate surgical margins can be obtained.

Data from retrospective studies comparing modified radical mastectomy with its radical counterpart (which included taking the muscle) consistently show the procedures result in an equivalent local recurrence rate and survival outcomes [12,68-70]. Additional support for simple mastectomy can also be drawn from studies in women that also demonstrated therapeutic equivalence of these two surgical procedures. Nipple- and skin-sparing mastectomy techniques have emerged as valuable tools in female breast cancer, but these have not been explored in male breast cancer, likely due to the constraints of tumor location and nipple involvement. However, the psychosocial distress described below suggests that greater attention to the cosmetic outcomes for men should not be ignored. Indeed, breast reconstruction has been performed in men seemingly for exactly this indication [71]. (See "[Mastectomy](#)".)

Although most men have a small volume of breast tissue, some have sufficient breast tissue to permit breast conservation therapy [72]. In a review of data from the Surveillance, Epidemiology, and End Results Program (SEER), 1541 cases of male breast cancer were identified, and almost 20 percent were treated with breast conservation [73]. While this study did not report outcomes, a subsequent SEER database analysis suggested that breast-conserving surgery is an acceptable alternative to mastectomy in some male patients ( [table 2](#)) [74]. Furthermore, one retrospective study of seven men treated with breast-conserving therapy followed for a median of 67 months reported that none experienced a recurrence of disease [72]. (See "[Breast-conserving therapy](#)".)

For most men who opt to proceed with breast-conserving surgery, adjuvant radiation therapy (RT) is thought to be essential. This is based on consistent results showing that adjuvant RT after breast-conserving surgery for women confers a survival advantage. However, extrapolating from data in older women with clinically node-negative, hormone receptor-positive breast cancer treated with adjuvant endocrine therapy, we offer men in the analogous clinical situation the option of omitting RT. Data in female breast cancer suggest that this approach yields similar overall survival and rates of distant metastases, although local recurrences are more frequent. (See "[Adjuvant radiation therapy for women with newly](#)

diagnosed, non-metastatic breast cancer", section on 'Possible omission of RT for select ER-positive, HER2-negative cancers'.)

**Management of the regional nodes** — Assessment of the regional nodes is an important aspect of surgical breast cancer management, as it is in women. We agree with an expert panel convened by the American Society of Clinical Oncology (ASCO) and feel that sentinel lymph node biopsy (SLNB) for men with clinically node-negative breast cancer is "acceptable" [75], and we suggest this approach over full axillary dissection in this setting.

Although the role of SLNB is established in women with clinically node-negative breast cancer, its proven role in men is less robust due to the rarity of male breast cancer. Although large studies establishing the sensitivity and specificity of SLNB in men with clinically node-negative breast cancer have not been carried out, smaller reports suggest it is feasible and accurate [76,77]. For example, as reported in a retrospective case review of 32 patients, 19 percent had an involved sentinel node, and there were no axillary recurrences at a median follow-up of 30 months [76]. SLNB in men is becoming more widely adopted. (See "[Overview of sentinel lymph node biopsy in breast cancer](#)".)

Men with a negative SLNB do not require further surgery. However, the role of a complete axillary node dissection for men with a positive SLNB is controversial. Given the lack of data to inform this issue, the approach to patients with a positive SLNB mirrors that for women. (See "[Overview of sentinel lymph node biopsy in breast cancer](#)".)

**Locally advanced disease** — Men who present with locally advanced disease (T3N0 or stage III disease) or inflammatory breast cancer are treated similarly to women who present in this way. We offer these patients neoadjuvant chemotherapy because randomized trials of neoadjuvant chemotherapy followed by surgery versus primary surgery followed by adjuvant chemotherapy, which have been predominantly performed in women, demonstrate that neoadjuvant chemotherapy is associated with high rates of clinical response and a higher likelihood for allowing cosmetically acceptable surgery without compromising survival outcomes. (See "[General principles of neoadjuvant management of breast cancer](#)".)

Additionally, patients with earlier-stage disease may be appropriate candidates for neoadjuvant therapy if they have triple-negative breast cancers or human epidermal growth factor receptor 2 (HER2)-positive tumors, since these patients generally receive chemotherapy at some point in their treatment course anyway, and these subtypes are associated with a high likelihood of response. (See "[General principles of neoadjuvant management of breast cancer](#)", section on 'Patient selection'.)

Following completion of chemotherapy, we proceed with a mastectomy in most patients, provided they have a sufficient response to make surgery feasible. For patients who do not have a sufficient response, an alternative regimen should be administered. (See ["Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer"](#), section on 'Locally advanced breast cancer' and ["Inflammatory breast cancer: Clinical features and treatment"](#) and ["General principles of neoadjuvant management of breast cancer"](#), section on 'Poor response to or progression on neoadjuvant therapy'.)

**Adjuvant therapy** — As in women, adjuvant treatments may include RT, endocrine therapy, chemotherapy, and anti-HER2 therapy. These are discussed below.

**Radiation therapy** — In the absence of high-quality data, the indications for RT for men with breast cancer mirror those for women. These include patients (see ["Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer"](#)):

- Who underwent breast-conserving surgery. Such patients are typically treated with whole-breast radiation and may also receive a boost to the tumor bed and, if axillary nodes are involved, axillary radiation.
- Who underwent a mastectomy for T4 or T3 disease (especially if associated with positive surgical margins or pathologic node involvement).
- Who had four or more involved lymph nodes.
- In addition to the above indications, we also suggest postmastectomy radiation for men with one to three involved nodes, although this approach is the subject of some debate, both in men and women. This recommendation is extrapolated from the data in women with the same extent of nodal disease, where trials indicate that RT reduces the risk of recurrence and potentially improves disease-specific survival. However, as in women, the modest locoregional and potential survival benefit from treatment must be weighed against the risk of treatment-related toxicities. (See ["Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer"](#).)

There are limited data regarding the indications for postmastectomy RT in men treated for breast cancer. In retrospective series, postmastectomy RT appears to reduce locoregional recurrence in men with breast cancer, but the influence on survival is not clear [12,54,78-81]. In the absence of high-quality data, these recommendations are extrapolated from the management of women with breast cancer.

## Systemic therapy

**Chemotherapy** — Prospective trials evaluating the benefits of adjuvant chemotherapy specifically for men with newly diagnosed breast cancer have not been performed. Therefore, the same guidelines for adjuvant systemic therapy in women with early-stage breast cancer are generally followed for men who have breast cancer [82].

- (See "[Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer](#)".)
- (See "[Adjuvant systemic therapy for HER2-positive breast cancer](#)".)

Extrapolating from data in women, we use the 21-gene Recurrence Score (RS) to guide decisions regarding adjuvant chemotherapy for men with hormone receptor-positive, HER2-negative breast cancer and either no or limited lymph node involvement. (See "[Deciding when to use adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer](#)", section on 'Recurrence Score'.)

Limited data in men suggest the RS may identify men with hormone receptor-positive breast cancer at sufficiently low risk for recurrence that adjuvant chemotherapy is unlikely to be of benefit. In a retrospective study of 38 male breast cancer patients with estrogen receptor (ER)-positive/HER2-negative breast cancer, all of whom were treated with total mastectomy (and one of whom received adjuvant radiotherapy), and 90 percent of whom received adjuvant endocrine therapy, RS was low ( $\leq 17$ ) in 26 cases (68 percent), intermediate (18 to 30) in 9 cases (24 percent), and high ( $\geq 31$ ) in 3 cases (13 percent) [83]. Chemotherapy was administered to no patients with low RS, 3 patients (67 percent) with intermediate RS, and 1 patient (33 percent) with a high RS. In the entire group, there was 1 recurrence, which occurred in a patient with intermediate RS and lymph node-positive disease who had received adjuvant endocrine therapy and chemotherapy.

Toxicities of standard chemotherapy regimens for breast cancer are also poorly studied in men, so prophylactic and treatment strategies (eg, for nausea and neutropenia) are extrapolated from women. Cardiac toxicity rates during and after anthracycline and HER2-directed therapies are particularly deserving of additional research in men.

**Endocrine therapy** — For men with hormone receptor-positive breast cancer, we recommend endocrine therapy following surgery rather than observation, given benefits observed in trials enrolling women with hormone receptor-positive breast cancer as well as retrospective evidence in male breast cancer. The data on endocrine therapy in women with newly diagnosed, hormone receptor-positive breast cancer are discussed separately. (See "[Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer](#)".)

Among the available agents, we prefer [tamoxifen](#) rather than an AI (in the absence of contraindications to tamoxifen [eg, hypercoagulable state]), consistent with guidelines from ASCO [84], although an AI with GnRHa is an acceptable alternative. Toxicities of treatment are discussed elsewhere. (See "[Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer](#)", section on 'Side effects' and "[Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer](#)", section on 'Side effects'.)

Retrospective evidence suggests improvements in overall survival for men with hormone receptor-positive disease treated with adjuvant [tamoxifen](#). For example, in a registry study including 392 male patients with hormone receptor-positive breast cancer (84 percent of whom had non-metastatic disease), adjuvant treatment with tamoxifen was associated with improved survival (hazard ratio [HR] 0.4, 95% CI 0.1-0.99) [85]. Similarly, in a retrospective study including 135 male patients with non-metastatic breast cancer, 115 of whom had ER-positive disease, and 38 of whom received adjuvant endocrine therapy, receipt of endocrine therapy was associated with improvement in overall survival (HR 0.45, 95% CI 0.25-0.84) [86]. Thirty-five of the 38 men receiving adjuvant endocrine therapy were treated with tamoxifen.

An explanation for the differential activity of AIs in men versus postmenopausal women is that testicular production of estrogen is not inhibited by an AI. Use of GnRHa may suppress this production and improve outcomes when used with AIs in men. The Male-GBG54 trial is a 50-patient prospective randomized phase II study evaluating [tamoxifen](#) with or without GnRHa versus an AI with GnRHa in male breast cancer patients [87]. In preliminary results, AI plus GnRHa therapy was associated with a 64 percent suppression in estradiol levels (compared with 35 percent with AI alone based on historical literature). Although there was no AI-alone arm in this study, it does provide some support for the use of GnRHa, if AI is going to be used in this setting.

On the basis of the Adjuvant [Tamoxifen](#): Longer Against Shorter (ATLAS) trial in women, which supported administration of 10 rather than 5 years of tamoxifen, men with higher-risk breast cancer based on tumor characteristics (eg, higher tumor grade, pathologic node involvement, and larger tumor size) and those who are tolerating treatment are appropriate candidates for extended tamoxifen treatment. For all others, a decision on whether to continue treatment beyond five years should be based on an individual consideration of their side effects (eg, hot flashes, sexual dysfunction). The results of the ATLAS trial are discussed separately. (See '[Breast cancer subtype](#)' above.)

Despite the potential survival benefits of [tamoxifen](#), several studies indicate that a large proportion of men discontinue treatment before five years, which may be associated with worse

outcomes [88,89]. In a study of 116 men, persistence rates fell from 65 percent at year 1 to 18 percent by year 5 [89]. Compared with men who were persistent with tamoxifen, low persistence was associated with a significantly lower ten-year rate of disease-free survival (DFS; 42 versus 73 percent, respectively;  $p = 0.007$ ) and overall survival (50 versus 80 percent;  $p = 0.008$ ). Factors associated with low persistence included:

- Age  $\leq 60$  years (HR 1.10, 95% CI 1.01-1.21)
- Lack of social support (HR 2.45, 95% CI 1.32-4.55)
- Onset of adverse effects (HR 2.19, 95% CI 1.57-3.04), including fatigue (21 percent), anxiety (20 percent), sleep disorders (19 percent), decreased libido (11 percent), and weight gain (10 percent)

Based upon these results, interventions are needed to improve the persistence of men with breast cancer to complete the full treatment course of [tamoxifen](#).

**Targeted agents in those with high-risk disease** — The adjuvant use of targeted agents such as inhibitors of cyclin-dependent kinase (CDK) 4/6 and poly(ADP-ribose) polymerase (PARP) in men with breast cancer follows the same principles as in women.

- Select patients with high-risk, node-positive, ER-positive, HER2-negative breast cancer are candidates for adjuvant treatment with the CDK 4/6 inhibitor [abemaciclib](#). Patient selection is discussed elsewhere. (See "[Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer](#)", section on '[Incorporation of targeted therapies for select patients](#)'.)
- For select patients with breast cancer susceptibility gene 1/2 (*BRCA1/2*) mutations and high-risk early, HER2-negative breast cancer, adjuvant treatment with [olaparib](#), an inhibitor of PARP, has been shown to improve disease-free survival outcomes. This is discussed in detail elsewhere. (See "[Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer](#)", section on '[BRCA carriers with high-risk disease](#)'.)

**Bisphosphonates** — Men with early-stage disease should not be treated with bone-modifying agents to prevent recurrence, but could still receive these agents to prevent or treat osteoporosis, according to guidelines from ASCO [84].

Although DFS benefits of bone-modifying agents have been observed in women, particularly in postmenopausal women receiving AIs, absolute improvements have been small and somewhat

inconsistent, and trials have never been conducted in men. (See "[Use of osteoclast inhibitors in early breast cancer](#)".)

**Prognosis** — Studies have evaluated survival in male breast cancer patients [[4,15,49,73,90-94](#)]:

- In the worldwide consortium analysis of 1500 male breast cancer patients discussed above, at a median follow-up of 8.2 years, the five-year breast cancer-specific mortality improved steadily in five-year increments from 15.1 (1990 to 1995) to 7.6 percent (2006 to 2010) [[46](#)]. Additionally, for patients with luminal A-like breast cancer, the median overall survival was 9.5 compared with 8.8 years in those with luminal B-like/HER2-negative breast cancer and 10 years for those with luminal B-like/HER2-positive breast cancer.
- In an analysis from the SEER database of male breast cancer patients diagnosed between 2005 and 2009, male breast cancer patients experienced a worse prognosis compared with women, with a risk of death that was 41 percent higher than females during the same period [[95](#)]. Similarly, the 5- and 10-year survival rates of male patients (85 and 73 percent, respectively) were lower than female patients (90 and 85 percent, respectively). These findings were similar across race and stage subgroups. Other analyses have also suggested worsened breast cancer-specific and overall survival in men compared with women with breast cancer [[96,97](#)]. As in women, tumor size and the presence as well as number of involved nodes are the most important prognostic factors for breast cancers in men [[12,15,54,91,98-104](#)].
- In two reports involving 335 and 397 cases of breast cancer in men, respectively [[12,104](#)], 10-year disease-specific survival rates were as follows:
  - Histologically negative nodes – 77 and 84 percent
  - One to three positive nodes – 50 and 44 percent
  - Four or more histologically positive nodes – 24 and 14 percent

RS is prognostic for men with hormone receptor-positive, HER2-negative breast cancer, as it is for women. In a retrospective analysis including 3800 men with hormone receptor-positive breast cancer, five-year breast cancer-specific survival was 99 percent for men with RS  $\leq 17$ , 96 percent for men with RS 18 to 30, and 81 percent for men RS  $\geq 31$  [[96](#)].

**Racial disparities** — As is the case in women, Black men with breast cancer have a worse prognosis than do White men [[10,105](#)].

This was illustrated in a report of 510 men aged 65 years or older (456 White Americans, 34 Black Americans) with stage I to III breast cancer derived from the linked Medicare/SEER database [105]. Treatment consisted of mastectomy, chemotherapy, and RT in 94, 28, and 29 percent of men, respectively.

Compared with White men, Black men were significantly more likely to have advanced-stage disease (eg, 24 versus 9 percent with stage III) and larger tumor size. In addition, there was a nonsignificant trend for Black men to have more node-positive disease (45 versus 34 percent) and poorly differentiated tumors (44 versus 32 percent), fewer hormone receptor-positive tumors (56 versus 72 percent), and comorbidity scores greater than 0 (53 versus 38 percent). Black men were approximately 50 percent less likely to be referred to a medical oncologist and to receive chemotherapy, but these differences were also not statistically significant. After adjusting for known clinical, demographic, and treatment-related factors, Black men had a greater than threefold increased risk of dying as a result of their breast cancer compared with White men. Five-year survival rates were 66 and 90 percent, respectively.

## Survivorship issues

**Post-treatment surveillance** — In general, men treated for breast cancer should undergo similar post-treatment surveillance as women. However, whether or not there is a role for mammography is not known. While limited data suggest these patients are at an increased risk of a contralateral breast cancer [106,107], the absolute risk appears to be low [17]. Our approach to screening, consistent with ASCO guidelines, is as follows [84]:

- Ipsilateral annual mammogram should be offered to men with a history of breast cancer treated with lumpectomy, regardless of genetic predisposition.
- Contralateral annual mammogram may be offered to men with a history of breast cancer and a genetic predisposing mutation. Although we do not suggest it for patients lacking a genetic mutation, we acknowledge that experts are divided in this regard [84]. More research is needed on the risk of contralateral breast cancers in men without cancer-predisposing genetic mutations.
- Breast magnetic resonance imaging is not recommended routinely.

However, the role of screening in men with a history of breast cancer is uncertain, and decision-making should take into account men's preferences and values.

As in women, these patients are also at risk for secondary malignancies [108,109]. This was shown in one study that included data from over 10,000 male breast cancer survivors, in which

the standardized incidence ratio (SIR) of a second primary cancer, relative to healthy male controls, was 1.3; specifically, there were increased colorectal (SIR 1.3), pancreatic (SIR 1.6) and thyroid (SIR 5.6) cancer risks [108]. Male breast cancer survivors should engage in cancer screening according to guidelines according to age, personal and family history, and genetic risk factors (if present), as discussed elsewhere. (See ["Screening for colorectal cancer in patients with a family history of colorectal cancer or advanced polyp"](#) and ["Familial risk factors for pancreatic cancer and screening of high-risk patients"](#) and ["Cancer risks and management of BRCA1/2 carriers without cancer"](#).)

**Physical and psychologic side effects** — Small studies suggest that toxicities are common in men on [tamoxifen](#), and that this is one of the major reasons for the high rate of endocrine therapy discontinuation in men [88,110,111].

Optimal management of endocrine therapy side effects such as hot flashes and sexual dysfunction is unknown in men, so strategies are usually extrapolated from those proven effective in female breast cancer survivors (for hot flashes) and the general population of men (for sexual dysfunction).

- Options for management of hot flashes include the same nonhormonal options that are offered to women with a history of breast cancer, such as selective serotonin reuptake inhibitors that do not interfere with metabolism of [tamoxifen](#) (eg, [venlafaxine](#)). (See ["Menopausal hot flashes"](#), section on 'Women with breast cancer'.)
- In general, sexual dysfunction in male breast cancer patients is treated similarly as in men without breast cancer, although we avoid the use of testosterone, as it has been suggested that metabolism of testosterone to estrogen derivatives can stimulate breast tissue [112]. Phosphodiesterase-5 inhibitors may be used for men with erectile dysfunction. (See ["Treatment of male sexual dysfunction"](#).)

Little is known about the experience of men after breast cancer. However, issues related to emasculation and psychologic distress appear to be common themes [113-116]. In one study that included over 160 men with breast cancer who were a median of 2.9 years out from diagnosis, psychologic distress consisted of [116]:

- Significant depression and anxiety (measured with the Hospitalized Anxiety and Depression Scale) were present in 1 and 6 percent of participants, respectively.
- Psychologic distress was significantly higher among men who underwent a mastectomy, those experiencing comorbid symptoms, and those who were not married.

- Cancer-related distress was significantly correlated with younger age, altered body image, more frequent use of engagement and avoidance coping, and greater perceived stressfulness due to reduced physical ability, pain, fear, and uncertainty about the future.

A more general discussion on survivorship care is covered separately. (See "[Overview of cancer survivorship care for primary care and oncology providers](#)" and "[Assuring quality of care for cancer survivors: The survivorship care plan](#)".)

---

## METASTATIC DISEASE

**Approach** — The approach to men with metastatic or advanced breast cancer is similar to that of women with metastatic breast cancer.

- Chemotherapy is administered to men in a similar fashion as for women, for appropriate candidates. (See "[Overview of the approach to metastatic breast cancer](#)".)
- For men with human epidermal growth factor receptor 2 (HER2)-positive disease, incorporation of HER2-directed agents into the treatment strategy is recommended, as for women. (See "[Systemic treatment for HER2-positive metastatic breast cancer](#)".)
- For those with metastatic, hormone receptor-positive, HER2-negative disease, endocrine therapies are often employed. However, in the setting of rapidly progressive or extensive visceral disease, chemotherapy is an alternative.
- Although data are mixed regarding survival benefits for local treatments in metastatic breast cancer, they may be appropriate for some men, in clinical scenarios analogous to women. (See "[The role of local therapies in metastatic breast cancer](#)".)

**Special considerations for hormone receptor-positive, HER2-negative disease** — For men with hormone receptor-positive, advanced breast cancer, the approach to choice of therapy is largely extrapolated from data in women with hormone receptor-positive breast cancer and is discussed below. (See "[Treatment for hormone receptor-positive, HER2-negative advanced breast cancer](#)".)

- For men who present with de novo, metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, we suggest the combination of either [tamoxifen](#) or an aromatase inhibitor (AI)/gonadotropin-releasing hormone agonist (GnRHa) with a cyclin-dependent kinase (CDK) 4/6 inhibitor [84]. [Palbociclib](#) and [ribociclib](#) have been approved by the US Food and Drug Administration (FDA) for men with metastatic, hormone receptor-positive breast cancer, in combination

with either an AI or [fulvestrant](#) [117,118], but [abemaciclib](#) is an appropriate off-label substitute. A choice between AI/GnRHa versus tamoxifen, among those who are also receiving a CDK 4/6 inhibitor, should be driven by patient preferences in regards to toxicity and scheduling, given lack of comparative data regarding efficacy.

- For men who have previously been treated with adjuvant [tamoxifen](#), or who have progressed on tamoxifen in the metastatic setting, we suggest an AI/GnRHa plus a CDK 4/6 inhibitor.

In either of the above cases, an acceptable alternative is to omit the CDK 4/6 inhibitor and administer endocrine therapy alone, especially for those with lower burden of disease or comorbidities, or due to patient preferences.

- We typically opt for [fulvestrant](#) as part of subsequent-line therapy after progression on an AI/GnRHa. If [palbociclib](#) has not yet been administered, we combine it with fulvestrant (with or without a GnRHa, depending on previous tolerance). For those whose tumors harbor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (*PIK3CA*) mutations and who have progressed on endocrine therapy, the addition of the alpha isoform-specific phosphoinositide-3 kinase (PI3K) inhibitor [alpelisib](#) to fulvestrant is another option.
- An AI/GnRHa/[everolimus](#) is an option for later-line therapy, which we typically reserve for use after progression on the above agents.

Below are the limited available data in men regarding endocrine therapy.

- **AIs with GnRHa** – Because AIs do not reduce testicular production of estrogens, we administer GnRHa concurrently with AI. Case studies of response to AI plus GnRHa have been reported, one of which was in a patient whose metastatic disease had progressed on both single-agent AI and single-agent GnRHa prior to responding to the combination [119]. Another pooled report of AI therapy alone or in combination with GnRHa in 23 men showed a partial response in 26.1 percent and stable disease in 56.5 percent.

Responses to single-agent AIs have also been documented [120-123], though we prefer to avoid AI monotherapy for reasons mentioned above. (See '[Endocrine therapy](#)' above.)

- **Tamoxifen** – Small, older, observational studies suggest that approximately 40 percent of men with hormone receptor-positive disease respond to [tamoxifen](#), though many patients in these older studies had prior orchiectomies, and the true response rate in male breast cancer may be higher [11,124-127]. Men with hormone receptor-negative breast cancer do

not appear to derive benefit from treatment. Tamoxifen is associated with hot flashes, sexual dysfunction, changes in mood, cataracts, leg cramps, and venous thromboembolism (VTE), with one study suggesting VTEs occurring in approximately 10 percent of men within the first 18 months of treatment [128]. (See "[Managing the side effects of tamoxifen and aromatase inhibitors](#)".)

- **Addition of CDK 4/6 inhibitors** – Inhibitors of CDK 4/6 have demonstrated activity in women when combined with endocrine therapy, but their use in men is not well-studied. A case report on fourth-line [letrozole](#) plus [palbociclib](#) in a man with metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer reported stable disease at four months on treatment [129].
- **Addition of a PI3K inhibitor** – The addition of [alpelisib](#) to [fulvestrant](#) improved progression-free survival for those with tumor *PIK3CA* mutations in the phase III SOLAR-1 trial. The trial mostly consisted of postmenopausal women, although one male patient was included. Full details of this trial are discussed elsewhere.
- **Addition of mechanistic target of rapamycin (mTOR) inhibitors** – Two case reports of heavily pretreated male patients receiving [everolimus](#) with either [tamoxifen](#) or [exemestane](#) reported favorable responses to therapy, although one patient had to stop treatment after four months due to stomatitis [130,131].
- **Fulvestrant** – Data regarding the role of [fulvestrant](#) are limited. Two case reports totaling seven men documented a partial response in two and stable disease (in one case lasting 22 months) in three others. A pooled analysis of 23 male patients receiving fulvestrant as first-, second-, or third-line treatment of metastatic disease reported a partial response rate of 26 percent, and an additional 48 percent had stable disease [132].
- **Later-line hormonal treatments** – Men responding to one form of hormonal treatment have a greater likelihood of responding to subsequent hormonal manipulations [127]. Other endocrine therapies (eg, aminoglutethimide, [megestrol acetate](#), androgens, antiandrogens, corticosteroids, [cyproterone acetate](#), estrogens) are associated with 50 to 70 percent response rates in ER-positive breast cancer [126,133-135]. However, side effect profiles tend to be less favorable than with [tamoxifen](#), and most have been poorly studied in men. Hence, they are reserved for subsequent-line therapy. Although bilateral orchiectomy yields response rates of 32 and 67 percent [11,125,136-138], we prefer medical options given the psychologic and physical impact of bilateral orchiectomy.

## SOCIETY GUIDELINE LINKS

Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "[Society guideline links: Hereditary breast and ovarian cancer](#)" and "[Society guideline links: Breast cancer](#)".)

## INFORMATION FOR PATIENTS

UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

- Basics topics (see "[Patient education: Breast cancer \(The Basics\)](#)")
- Beyond the Basics topics (see "[Patient education: Treatment of metastatic breast cancer \(Beyond the Basics\)](#)")

## SUMMARY AND RECOMMENDATIONS

- Breast cancer is much less common in men than in women. Men tend to present at an older age than women. Men with breast cancer should be referred for genetic counseling and testing. (See '[Epidemiology and risk factors](#)' above and "[Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes](#)", section on '[Concerning personal or family history](#)'.)
- Biopsy is required to confirm the diagnosis and assay for hormone receptors and human epidermal growth factor receptor 2 (HER2) expression, both of which may influence the selection of treatment. (See '[Diagnostic evaluation and staging](#)' above.)

- Most men with early-stage breast cancer are treated with mastectomy rather than lumpectomy due to limited breast tissue. However, for men with sufficient breast tissue to be candidates for breast conservation, either mastectomy or breast-conserving therapy are appropriate options. For men who pursue breast-conserving surgery, we recommend adjuvant radiation therapy (RT) (**Grade 1B**). (See ['Early-stage disease'](#) above and ['Radiation therapy'](#) above.)
- As in women, surgical evaluation of the axillary lymph nodes is required. (See ['Management of the regional nodes'](#) above.)
  - For men with a clinically positive axilla, as in women, we recommend axillary lymph node dissection (**Grade 1B**). (See ["Overview of management of the regional lymph nodes in breast cancer"](#) and ["Overview of management of the regional lymph nodes in breast cancer"](#), section on ['Axillary evaluation'](#).)
  - For patients with a clinically uninvolved axilla, we suggest a sentinel lymph node biopsy (SLNB) instead of full axillary node dissection (**Grade 2B**).
    - Men with a negative SLNB do not require further surgery. However, the role of a complete axillary node dissection for men with a positive SLNB is controversial. Given the lack of data to inform this issue, the approach to patients with a positive SLNB mirrors that for women. (See ["Overview of sentinel lymph node biopsy in breast cancer"](#).)
- As in women, for men with locally advanced breast cancer (ie, T3 or T4 disease) and/or four or more involved axillary nodes, we recommend postoperative chest wall and regional lymph node irradiation following surgery (**Grade 1B**). For those with one to three involved lymph nodes or high-risk primary tumors, we also suggest regional nodal RT (**Grade 2B**), as in women. (See ['Radiation therapy'](#) above and ["Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer"](#).)
- The approach to adjuvant systemic therapy (ie, chemotherapy and/or HER2-directed therapy) for men with newly diagnosed breast cancer mirrors that for women. (See ["Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer"](#) and ["Adjuvant systemic therapy for HER2-positive breast cancer"](#).)
- For those with hormone receptor-positive disease,
  - If **early stage**, we suggest adjuvant [tamoxifen](#) rather than an aromatase inhibitor (AI) (**Grade 2C**), given insufficient evidence to support AI monotherapy for men. We also

suggest adjuvant tamoxifen over an AI with gonadotropin-releasing hormone agonists (GnRHa) (**Grade 2C**), given better tolerability. However, for those with contraindications to tamoxifen (eg, hypercoagulable state), an AI with GnRHa is an acceptable alternative. (See 'Endocrine therapy' above.)

- If **metastatic**, we suggest the addition of a cyclin-dependent kinase (CDK) 4/6 inhibitor to either [tamoxifen](#) or an AI/GnRHa, rather than these therapies alone (**Grade 2B**). However, data in this area are extremely limited, and it is an acceptable alternative to omit [palbociclib](#) and administer endocrine therapy alone, especially for those with lower burden of disease or comorbidities, or due to patient preferences. When using an AI, we suggest addition of a GnRHa, given possible ongoing testicular production of estrogen when an AI is used as monotherapy in men.
- Although evidence for CDK 4/6 inhibitors [fulvestrant](#), [alpelisib](#), and [everolimus](#) is limited in men, we incorporate these agents into metastatic disease treatment using a similar approach as in women. When using an AI (with or without a targeted therapy), we use a GnRHa to suppress testicular production of estrogen. (See 'Metastatic disease' above.)

Use of UpToDate is subject to the [Terms of Use](#).

## REFERENCES

1. White J, Kearins O, Dodwell D, et al. Male breast carcinoma: increased awareness needed. *Breast Cancer Res* 2011; 13:219.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019; 69:7.
3. Giordano SH. Breast Cancer in Men. *N Engl J Med* 2018; 378:2311.
4. Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? *Breast Cancer Res Treat* 2004; 83:77.
5. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017; 67:7.
6. Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. *Int J Cancer* 1993; 53:538.
7. Agrawal A, Ayantunde AA, Rampaul R, Robertson JF. Male breast cancer: a review of clinical management. *Breast Cancer Res Treat* 2007; 103:11.
8. Rudlowski C. Male Breast Cancer. *Breast Care (Basel)* 2008; 3:183.
9. Thomas DB. Breast cancer in men. *Epidemiol Rev* 1993; 15:220.

10. O'Malley CD, Prehn AW, Shema SJ, Glaser SL. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. *Cancer* 2002; 94:2836.
11. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. *Ann Intern Med* 2002; 137:678.
12. Cutuli B, Lacroze M, Dilhuydy JM, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. *Eur J Cancer* 1995; 31A:1960.
13. Mabuchi K, Bross DS, Kessler II. Risk factors for male breast cancer. *J Natl Cancer Inst* 1985; 74:371.
14. Nahleh ZA, Srikantiah R, Safa M, et al. Male breast cancer in the veterans affairs population: a comparative analysis. *Cancer* 2007; 109:1471.
15. Giordano SH, Cohen DS, Buzdar AU, et al. Breast carcinoma in men: a population-based study. *Cancer* 2004; 101:51.
16. Ferzoco RM, Ruddy KJ. The Epidemiology of Male Breast Cancer. *Curr Oncol Rep* 2016; 18:1.
17. Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. *Ann Oncol* 2013; 24:1434.
18. Hogervorst FB, Cornelis RS, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. *Nat Genet* 1995; 10:208.
19. Struwing JP, Brody LC, Erdos MR, et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. *Am J Hum Genet* 1995; 57:1.
20. Ottini L, Masala G, D'Amico C, et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. *Cancer Res* 2003; 63:342.
21. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. *J Clin Oncol* 2004; 22:735.
22. Machado PM, Brandão RD, Cavaco BM, et al. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. *J Clin Oncol* 2007; 25:2027.
23. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2007; 99:1811.
24. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. *Am J Hum Genet* 1997; 61:120.
25. Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer

- cases and breast cancer families. *Nat Genet* 1996; 13:123.
26. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. *Am J Hum Genet* 1997; 60:1079.
  27. Csokay B, Udvarhelyi N, Sulyok Z, et al. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. *Cancer Res* 1999; 59:995.
  28. Friedman LS, Gayther SA, Kurosaki T, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. *Am J Hum Genet* 1997; 60:313.
  29. Mavraki E, Gray IC, Bishop DT, Spurr NK. Germline BRCA2 mutations in men with breast cancer. *Br J Cancer* 1997; 76:1428.
  30. Haraldsson K, Loman N, Zhang QX, et al. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. *Cancer Res* 1998; 58:1367.
  31. Díez O, Cortés J, Domènech M, et al. BRCA2 germ-line mutations in Spanish male breast cancer patients. *Ann Oncol* 2000; 11:81.
  32. Domchek SM, Eisen A, Calzone K, et al. Application of breast cancer risk prediction models in clinical practice. *J Clin Oncol* 2003; 21:593.
  33. Sverdlov RS, Barshack I, Bar Sade RB, et al. Genetic analyses of male breast cancer in Israel. *Genet Test* 2000; 4:313.
  34. Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. *Breast Cancer Res* 2002; 4:R2.
  35. Struewing JP, Coriaty ZM, Ron E, et al. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. *Am J Hum Genet* 1999; 65:1800.
  36. Ding YC, Steele L, Kuan CJ, et al. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. *Breast Cancer Res Treat* 2011; 126:771.
  37. Silvestri V, Rizzolo P, Zanna I, et al. PALB2 mutations in male breast cancer: a population-based study in Central Italy. *Breast Cancer Res Treat* 2010; 122:299.
  38. Boyd J, Rhei E, Federici MG, et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. *Breast Cancer Res Treat* 1999; 53:87.
  39. Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelter's syndrome. *J Med Genet* 1971; 8:460.
  40. Scheike O, Visfeldt J, Petersen B. Male breast cancer. 3. Breast carcinoma in association with the Klinefelter syndrome. *Acta Pathol Microbiol Scand A* 1973; 81:352.

41. Hultborn R, Hanson C, Köpf I, et al. Prevalence of Klinefelter's syndrome in male breast cancer patients. *Anticancer Res* 1997; 17:4293.
42. Brinton LA. Breast cancer risk among patients with Klinefelter syndrome. *Acta Paediatr* 2011; 100:814.
43. Thomas DB, Jimenez LM, McTiernan A, et al. Breast cancer in men: risk factors with hormonal implications. *Am J Epidemiol* 1992; 135:734.
44. de Vries S, Krul IM, Schaapveld M, et al. Risk of male breast cancer after Hodgkin lymphoma. *Blood* 2023; 142:806.
45. Culell P, Solernou L, Tarazona J, et al. Male breast cancer: a multicentric study. *Breast J* 2007; 13:213.
46. Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. *Ann Oncol* 2018; 29:405.
47. Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). *Ann Oncol* 2017; 28:3111.
48. Goss PE, Reid C, Pintilie M, et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. *Cancer* 1999; 85:629.
49. Vermeulen MA, Slaets L, Cardoso F, et al. Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. *Eur J Cancer* 2017; 82:219.
50. Michaels BM, Nunn CR, Roses DF. Lobular carcinoma of the male breast. *Surgery* 1994; 115:402.
51. Camus MG, Joshi MG, Mackarem G, et al. Ductal carcinoma in situ of the male breast. *Cancer* 1994; 74:1289.
52. Anderson WF, Devesa SS. In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. *Cancer* 2005; 104:1733.
53. Hittmair AP, Lininger RA, Tavassoli FA. Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma--a preliminary report. *Cancer* 1998; 83:2139.
54. Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multiinstitutional survey. *Cancer* 1998; 83:498.
55. Desai DC, Brennan EJ Jr, Carp NZ. Paget's disease of the male breast. *Am Surg* 1996; 62:1068.

56. Takeuchi T, Komatsuzaki M, Minesaki Y, et al. Paget's disease arising near a male areola without an underlying carcinoma. *J Dermatol* 1999; 26:248.
57. Spigel JJ, Evans WP, Grant MD, et al. Male inflammatory breast cancer. *Clin Breast Cancer* 2001; 2:153.
58. Chavez-Macgregor M, Clarke CA, Lichtensztajn D, et al. Male breast cancer according to tumor subtype and race: a population-based study. *Cancer* 2013; 119:1611.
59. Evans GF, Anthony T, Turnage RH, et al. The diagnostic accuracy of mammography in the evaluation of male breast disease. *Am J Surg* 2001; 181:96.
60. Dershaw DD, Borgen PI, Deutch BM, Liberman L. Mammographic findings in men with breast cancer. *AJR Am J Roentgenol* 1993; 160:267.
61. Appelbaum AH, Evans GF, Levy KR, et al. Mammographic appearances of male breast disease. *Radiographics* 1999; 19:559.
62. Joshi A, Kapila K, Verma K. Fine needle aspiration cytology in the management of male breast masses. Nineteen years of experience. *Acta Cytol* 1999; 43:334.
63. Westenend PJ, Jobse C. Evaluation of fine-needle aspiration cytology of breast masses in males. *Cancer* 2002; 96:101.
64. Vetto J, Schmidt W, Pommier R, et al. Accurate and cost-effective evaluation of breast masses in males. *Am J Surg* 1998; 175:383.
65. Lattin GE Jr, Jesinger RA, Mattu R, Glassman LM. From the radiologic pathology archives: diseases of the male breast: radiologic-pathologic correlation. *Radiographics* 2013; 33:461.
66. American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th ed, Amin MB, Edge SB, Greene FL, et al (Eds), Springer, Chicago 2017.
67. Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. *Breast Cancer Res Treat* 2013; 137:465.
68. Ouriel K, Lotze MT, Hinshaw JR. Prognostic factors of carcinoma of the male breast. *Surg Gynecol Obstet* 1984; 159:373.
69. Digenis AG, Ross CB, Morrison JG, et al. Carcinoma of the male breast: a review of 41 cases. *South Med J* 1990; 83:1162.
70. Gough DB, Donohue JH, Evans MM, et al. A 50-year experience of male breast cancer: is outcome changing? *Surg Oncol* 1993; 2:325.
71. Spear SL, Bowen DG. Breast reconstruction in a male with a transverse rectus abdominis flap. *Plast Reconstr Surg* 1998; 102:1615.

72. Golshan M, Rusby J, Dominguez F, Smith BL. Breast conservation for male breast carcinoma. *Breast* 2007; 16:653.
73. Gnerlich JL, Deshpande AD, Jeffe DB, et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. *Ann Surg Oncol* 2011; 18:1837.
74. Zaenger D, Rabatic BM, Dasher B, Mourad WF. Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer? *Clin Breast Cancer* 2016; 16:101.
75. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. *J Clin Oncol* 2005; 23:7703.
76. Gentilini O, Chagas E, Zurrida S, et al. Sentinel lymph node biopsy in male patients with early breast cancer. *Oncologist* 2007; 12:512.
77. Martin-Marcuatu JJ, Alvarez-Perez RM, Sousa Vaquero JM, Jimenez-Hoyuela García JM. Selective sentinel lymph node biopsy in male breast cancer. *Rev Esp Med Nucl Imagen Mol (Engl Ed)* 2018; 37:146.
78. Abrams MJ, Koffer PP, Wazer DE, Hepel JT. Postmastectomy Radiation Therapy Is Associated With Improved Survival in Node-Positive Male Breast Cancer: A Population Analysis. *Int J Radiat Oncol Biol Phys* 2017; 98:384.
79. Spence RA, MacKenzie G, Anderson JR, et al. Long-term survival following cancer of the male breast in Northern Ireland. A report of 81 cases. *Cancer* 1985; 55:648.
80. Erlichman C, Murphy KC, Elhakim T. Male breast cancer: a 13-year review of 89 patients. *J Clin Oncol* 1984; 2:903.
81. Schuchardt U, Seegenschmiedt MH, Kirschner MJ, et al. Adjuvant radiotherapy for breast carcinoma in men: a 20-year clinical experience. *Am J Clin Oncol* 1996; 19:330.
82. Giordano SH. A review of the diagnosis and management of male breast cancer. *Oncologist* 2005; 10:471.
83. Turashvili G, Gonzalez-Loperena M, Brogi E, et al. The 21-Gene Recurrence Score in Male Breast Cancer. *Ann Surg Oncol* 2018; 25:1530.
84. Hassett MJ, Somerfield MR, Baker ER, et al. Management of Male Breast Cancer: ASCO Guideline. *J Clin Oncol* 2020; 38:1849.
85. Harlan LC, Zujewski JA, Goodman MT, Stevens JL. Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival. *Cancer* 2010; 116:3558.
86. Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. *Cancer* 2005; 104:2359.

87. Reinisch M, Seiler S, Hauzenberger T, et al. Male-GBG54: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients. *Cancer Res* 2018; 78S: SABCS #PD7-10.
88. Anelli TF, Anelli A, Tran KN, et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. *Cancer* 1994; 74:74.
89. Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. *Breast Cancer Res Treat* 2012; 136:495.
90. Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. *Surgery* 1999; 126:775.
91. Herman K, Lobaziewicz W, Skotnicki P, et al. Male breast cancer. Does the prognosis differ compared to female? *Neoplasma* 2000; 47:191.
92. Borgen PI, Senie RT, McKinnon WM, Rosen PP. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. *Ann Surg Oncol* 1997; 4:385.
93. Willsher PC, Leach IH, Ellis IO, et al. A comparison outcome of male breast cancer with female breast cancer. *Am J Surg* 1997; 173:185.
94. El-Tamer MB, Komenaka IK, Troxel A, et al. Men with breast cancer have better disease-specific survival than women. *Arch Surg* 2004; 139:1079.
95. Liu N, Johnson KJ, Ma CX. Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis. *Clin Breast Cancer* 2018; 18:e997.
96. Massarweh SA, Sledge GW, Miller DP, et al. Molecular Characterization and Mortality From Breast Cancer in Men. *J Clin Oncol* 2018; 36:1396.
97. Wang F, Shu X, Meszoely I, et al. Overall Mortality After Diagnosis of Breast Cancer in Men vs Women. *JAMA Oncol* 2019; 5:1589.
98. Joshi MG, Lee AK, Loda M, et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. *Cancer* 1996; 77:490.
99. Borgen PI, Wong GY, Vlamis V, et al. Current management of male breast cancer. A review of 104 cases. *Ann Surg* 1992; 215:451.
100. Yap HY, Tashima CK, Blumenschein GR, Eckles NE. Male breast cancer: a natural history study. *Cancer* 1979; 44:748.
101. Salvadori B, Saccozzi R, Manzari A, et al. Prognosis of breast cancer in males: an analysis of 170 cases. *Eur J Cancer* 1994; 30A:930.

102. Vetto J, Jun SY, Paduch D, et al. Stages at presentation, prognostic factors, and outcome of breast cancer in males. *Am J Surg* 1999; 177:379.
103. Williams WL Jr, Powers M, Wagman LD. Cancer of the male breast: a review. *J Natl Med Assoc* 1996; 88:439.
104. Guinee VF, Olsson H, Moller T, et al. The prognosis of breast cancer in males. A report of 335 cases. *Cancer* 1993; 71:154.
105. Crew KD, Neugut AI, Wang X, et al. Racial disparities in treatment and survival of male breast cancer. *J Clin Oncol* 2007; 25:1089.
106. Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men. *J Natl Cancer Inst* 2002; 94:1330.
107. Dong C, Hemminki K. Second primary breast cancer in men. *Breast Cancer Res Treat* 2001; 66:171.
108. Allen I, Hassan H, Sofianopoulou E, et al. Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis. *Br J Cancer* 2022; 127:1660.
109. Hemminki K, Scélo G, Boffetta P, et al. Second primary malignancies in patients with male breast cancer. *Br J Cancer* 2005; 92:1288.
110. Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. *Ann Oncol* 2012; 23:1471.
111. Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. *Curr Oncol* 2010; 17:17.
112. Kenemans P, van der Mooren MJ. Androgens and breast cancer risk. *Gynecol Endocrinol* 2012; 28 Suppl 1:46.
113. Donovan T, Flynn M. What makes a man a man? The lived experience of male breast cancer. *Cancer Nurs* 2007; 30:464.
114. Bunkley DT, Robinson JD, Bennet NE Jr, Gordon S. Breast cancer in men: emasculation by association? *J Clin Psychol Med Settings* 2000; 7:91.
115. France L, Michie S, Barrett-Lee P, et al. Male cancer: a qualitative study of male breast cancer. *Breast* 2000; 9:343.
116. Brain K, Williams B, Iredale R, et al. Psychological distress in men with breast cancer. *J Clin Oncol* 2006; 24:95.
117. Palbociclib capsules. United States Prescribing Information. US National Library of Medicine. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/207103s008lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103s008lbl.pdf) (Accessed

d on July 08, 2019).

118. Ribociclib tablets. United States Prescribing Information. US National Library of Medicine. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/209092s008lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf) (Accessed on December 14, 2021).
119. Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. *J Clin Oncol* 2006; 24:e42.
120. Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. *J Surg Oncol* 2005; 90:26.
121. Italiano A, Largillier R, Marcy PY, et al. [Complete remission obtained with letrozole in a man with metastatic breast cancer]. *Rev Med Interne* 2004; 25:323.
122. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. *Am J Clin Oncol* 2002; 25:235.
123. Doyen J, Italiano A, Largillier R, et al. Aromatase inhibition in male breast cancer patients: biological and clinical implications. *Ann Oncol* 2010; 21:1243.
124. Ribeiro GG. Tamoxifen in the treatment of male breast carcinoma. *Clin Radiol* 1983; 34:625.
125. Kantarjian H, Yap HY, Hortobagyi G, et al. Hormonal therapy for metastatic male breast cancer. *Arch Intern Med* 1983; 143:237.
126. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. *Ann Intern Med* 1992; 117:771.
127. Lopez M, Di Lauro L, Lazzaro B, Papaldo P. Hormonal treatment of disseminated male breast cancer. *Oncology* 1985; 42:345.
128. Eggemann H, Bernreiter AL, Reinisch M, et al. Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. *Br J Cancer* 2019; 120:301.
129. Sorscher S. A First Case of Male Breast Cancer Responding to Combined Aromatase Inhibitor/Palbociclib Therapy. *Int J Cancer Clin Res* 2016; 3:069.
130. Ballatore Z, Pistelli M, Battelli N, et al. Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report. *BMC Res Notes* 2016; 9:497.
131. Kattan J, Kourie HR. The use of everolimus to reverse tamoxifen resistance in men with metastatic breast cancer: a case report. *Invest New Drugs* 2014; 32:1046.
132. Zagouri F, Sergentanis TN, Chrysikos D, et al. Fulvestrant and male breast cancer: a pooled analysis. *Breast Cancer Res Treat* 2015; 149:269.

133. Labrie F, Dupont A, Bélanger A, et al. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. *Clin Invest Med* 1990; 13:275.
134. Lopez M, Natali M, Di Lauro L, et al. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. *Cancer* 1993; 72:502.
135. Doberauer C, Niederle N, Schmidt CG. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. *Cancer* 1988; 62:474.
136. Stierer M, Rosen H, Weitensfelder W, et al. Male breast cancer: Austrian experience. *World J Surg* 1995; 19:687.
137. Kraybill WG, Kaufman R, Kinne D. Treatment of advanced male breast cancer. *Cancer* 1981; 47:2185.
138. Patel JK, Nemoto T, Dao TL. Metastatic breast cancer in males. Assessment of endocrine therapy. *Cancer* 1984; 53:1344.

Topic 779 Version 70.0

## GRAPHICS

### BRCA2 mutations in male breast cancer

Author; year	Men tested	Men with <i>BRCA2</i> mutations	% of men with <i>BRCA2</i> mutations	% of men with positive family history
Couch, FJ; 1996	50	7	14	80
Thorlacius, S; 1996	30	12	40	25
Friedman, LS; 1997	54	2	4	17
Mavraki, E; 1997	28	3	11	36
Haraldsson, K; 1998	34	7	21	13
Csokay, B; 1999	18	6	33	0
Diez, O; 2000	17	3	18	53
Sverdlov, R; 2000	31	1	3	35
Kwiatkowska, E; 2001	37	4	11	13
Basham, V; 2002	94	3	8	20
Frank, TS; 2002	76	14	18	36
Ottini, L; 2003	25	4	16	28
Ding, Y; 2011	115	18	16	22

Graphic 80912 Version 4.0

## Prognosis for stage I and II male breast cancer\*

<b>Surgery</b>	<b>Radiation</b>	<b>Stage I (%)</b>	<b>Stage II (%)</b>
BCS	No RT	96	91.8
	RT (BCT)	100 <sup>¶</sup>	100
SM	No RT	97.4	91.2

	RT	100	73.2
MRM	No RT	97.3	91.2
	RT	100¶	93.6

Data presented as n (95% CI).

BCS: breast-conserving surgery; RT: radiation therapy; BCT: breast conservation therapy; SM: simple mastectomy; MRM: modified radical mastectomy; CI: confidence interval.

\* Five-year cancer-specific survival rates.

¶ 95% CI unable to be calculated.

*Original table modified for this publication. From: Zaenger D, Rabatic BM, Dasher B, Mourad WF. Is breast-conserving therapy a safe modality for early-stage male breast cancer? Clin Breast Cancer 2016; 16:101. Table used with the permission of Elsevier Inc. All rights reserved.*

Graphic 116625 Version 1.0

## Contributor Disclosures

**William J Gradishar, MD** Grant/Research/Clinical Trial Support: Breast Cancer Research Foundation [Breast cancer]. Consultant/Advisory Boards: AbbVie [Breast cancer]; AstraZeneca [Breast cancer]; Daiichi Sankyo [Breast cancer]; Merck [Breast cancer]; Pfizer [Breast cancer]; Seattle Genetics [Breast cancer]; Stemline [Breast cancer]. All of the relevant financial relationships listed have been mitigated. **Kathryn J Ruddy, MD, MPH** No relevant financial relationship(s) with ineligible companies to disclose. **Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)** Consultant/Advisory Boards: Guardant Health [Breast cancer]; Merck [Breast cancer]; Novartis [Breast cancer]; Protean BioDiagnostics [Breast cancer]; Sanofi-Aventis [Breast cancer]. Speaker's Bureau: Merck [Breast cancer]. All of the relevant financial relationships listed have been mitigated. **Claudine Isaacs, MD** Grant/Research/Clinical Trial Support: AstraZeneca [Breast cancer, hereditary breast cancer]; Bristol Myers Squibb [Breast cancer, hereditary breast cancer]; Genentech [Breast cancer, hereditary breast cancer]; Novartis [Breast cancer, hereditary breast cancer]; Pfizer [Breast cancer, hereditary breast cancer]; Seattle Genetics [Breast cancer, hereditary breast cancer]; Tesaro/GSK [Breast cancer, hereditary breast cancer]. Consultant/Advisory Boards: AstraZeneca [Breast cancer, hereditary breast cancer]; Genentech [Breast cancer]; Gilead [Breast cancer]; ION [Breast cancer]; Novartis [Breast cancer]; Pfizer [Breast cancer, hereditary breast cancer]; PUMA [Breast cancer]; Seattle Genetics [Breast cancer]. Other Financial Interest: McGraw Hill [Royalties: Breast cancer]; SideOut Foundation [Medical Director]. All of the relevant financial relationships listed have been mitigated. **Sadhna R Vora, MD** No relevant financial relationship(s) with ineligible companies to disclose.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

### [Conflict of interest policy](#)

→